Based on our findings that FN1 deposition is increased in patients with AD and APOE dosage correlates with FN1 levels, we hypothesized that FN1 deposition could be a downstream driver of the pathological effects of APOEε4 in AD. This evidence concerns the gene APOE and Alzheimer disease.